Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Between Bedside and Bench
  • Published:

Getting away from glucose: stop sugarcoating diabetes

Type 2 diabetes is often viewed as a disorder of glucose metabolism. But many factors come into play in this condition, with obesity a prime risk factor and cardiovascular disease a major result. In Bedside to Bench, Babak Razani and Clay Semenkovich examine the linkages between diabetes and cardiovascular disease. They call for new research approaches in the wake of clinical trials showing that lowering glucose levels does not decrease cardiovascular events in people with type 2 diabetes. In Bench to Bedside, Steven Shoelson and Allison Goldfine examine how type 2 diabetes and other disorders can stem from obesity—and its effect on inflammation. These authors take a look at two recent studies showing how obesity perturbs inflammatory gene networks.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic representation of how intracellular energy depletion caused by diabetes might lead to coronary artery inflammation through effects on genotoxic stress and autophagy.

References

  1. Gerstein, H.C. et al. N. Engl. J. Med. 358, 2545–2559 (2008).

    Article  CAS  Google Scholar 

  2. Patel, A. et al. N. Engl. J. Med. 358, 2560–2572 (2008).

    Article  CAS  Google Scholar 

  3. Duckworth, W. et al. N. Engl. J. Med. 360, 129–139 (2009).

    Article  CAS  Google Scholar 

  4. University Group Diabetes Program. Diabetes 31, Suppl. 5, 1–81 (1982).

  5. UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).

  6. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977–986 (1993).

  7. Nathan, D.M. et al. N. Engl. J. Med. 353, 2643–2653 (2005).

    Article  Google Scholar 

  8. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. & Neil, H.A. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  9. Doria, A. et al. J. Am. Med. Assoc. 300, 2389–2397 (2008).

    Article  CAS  Google Scholar 

  10. Schneider, J.G. et al. Cell Metab. 4, 377–389 (2006).

    Article  CAS  Google Scholar 

  11. Bensaad, K. et al. Cell 126, 107–120 (2006).

    Article  CAS  Google Scholar 

  12. Budanov, A.V. & Karin, M. Cell 134, 451–460 (2008).

    Article  CAS  Google Scholar 

  13. Levine, B. & Deretic, V. Nat. Rev. Immunol. 7, 767–777 (2007).

    Article  CAS  Google Scholar 

  14. Matsui, Y. et al. Circ. Res. 100, 914–922 (2007).

    Article  CAS  Google Scholar 

  15. Jung, H.S. et al. Cell Metab. 8, 318–324 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

B.R. is supported by the Pfizer Junior Fellows Program at Washington University. C.F.S. has received speaker’s fees from Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Razani, B., Semenkovich, C. Getting away from glucose: stop sugarcoating diabetes. Nat Med 15, 372–373 (2009). https://doi.org/10.1038/nm0409-372

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0409-372

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing